PERSPECTIVE THERAPEUTICS, INC. Non Peo Neo Avg Comp Actually Paid Amt
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Non Peo Neo Avg Comp Actually Paid Amt of $1.49 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-16.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-16
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $1.49M DEF 14A · filed 2026-04-16 |
| 2024-12-31 | $942.51K DEF 14A · filed 2026-04-16 |
| 2023-12-31 | $1.21M DEF 14A · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |